|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0040808,
umls-concept:C0132326,
umls-concept:C0205195,
umls-concept:C0205210,
umls-concept:C0384228,
umls-concept:C0596545,
umls-concept:C0681850,
umls-concept:C0909839,
umls-concept:C1550501,
umls-concept:C1706203,
umls-concept:C2349001,
umls-concept:C2697811
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2011-4-25
|
|
pubmed:abstractText |
We retrospectively evaluated the durability and reasons for discontinuation of nevirapine (NVP) in combination with a tenofovir (TDF) and emtricitabine (FTC) or lamivudine (3TC)-containing antiretroviral therapy (ART) regimen in an Australian outpatient setting. Between January 2003 and June 2009, 64 patients (29 naïve and 35 treatment-experienced) received NVP/TDF-based regimens. The median exposure was 13.0 months (interquartile range [IQR] 6.0-20.0 months). The two- and three-year probability of continuing a NVP/TDF with FTC or 3TC regimen was 76% and 70%, respectively. Thirteen (20.3%) patients discontinued their regimen during the observation period. Reasons for discontinuation included virological failure in four (6.3%), rash in three (4.7%), lost to follow-up in three (4.7%), liver toxicity in two (3.1%) and HIV-1-related encephalopathy in one (1.6%). Long-term follow-up with a NVP/TDF-based regimen showed a low rate of discontinuation and enabled physicians to extend the use of ART over a long period, often with simplified (once-daily) regimens.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1758-1052
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
228-30
|
|
pubmed:meshHeading |
pubmed-meshheading:21515757-Adenine,
pubmed-meshheading:21515757-Adult,
pubmed-meshheading:21515757-Anti-HIV Agents,
pubmed-meshheading:21515757-Australia,
pubmed-meshheading:21515757-Deoxycytidine,
pubmed-meshheading:21515757-Drug Administration Schedule,
pubmed-meshheading:21515757-Female,
pubmed-meshheading:21515757-HIV Infections,
pubmed-meshheading:21515757-HIV-1,
pubmed-meshheading:21515757-Humans,
pubmed-meshheading:21515757-Lamivudine,
pubmed-meshheading:21515757-Lost to Follow-Up,
pubmed-meshheading:21515757-Male,
pubmed-meshheading:21515757-Medical Audit,
pubmed-meshheading:21515757-Middle Aged,
pubmed-meshheading:21515757-Nevirapine,
pubmed-meshheading:21515757-Phosphonic Acids,
pubmed-meshheading:21515757-Reverse Transcriptase Inhibitors,
pubmed-meshheading:21515757-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
|
|
pubmed:affiliation |
Albion Street Centre, Surry Hills, Australia. Don.Smith@sesiahs.health.nsw.gov.au
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
